PeptideScouterPeptideScouterIndex

Generic Mounjaro and Zepbound: Lilly's 14 Patent Suits

· Regulatory · News

On August 6, 2026, Eli Lilly and Company filed 14 patent infringement lawsuits in the U.S. District Court for the District of Delaware against drugmakers seeking Food and Drug Administration (FDA) approval to sell generic versions of Mounjaro and Zepbound, its two tirzepatide medicines. Each defendant had submitted an abbreviated new drug application (ANDA), the application a generic manufacturer files to copy an approved drug, certifying that Lilly's patents are invalid or will not be infringed.

The 14 cases cover 29 ANDAs and ten patents, and all are before Judge Jennifer L. Hall. As of November 18, 2026, every defendant has answered, ten of them with counterclaims against Lilly. Under federal drug law, FDA cannot make any of these approvals effective before November 13, 2029 unless the court first rules the patents invalid or not infringed.

Why fourteen suits on one day

Tirzepatide was a new active ingredient when FDA approved Mounjaro on May 13, 2022. For a new chemical entity, the law bars any ANDA that refers to the drug for five years after approval, with one exception. After four years, an applicant may file if its application certifies that a listed patent is invalid or will not be infringed. This is called a Paragraph IV certification, after the clause of the statute that defines it. FDA's Orange Book, its register of approved drugs and their patents, lists the same new chemical entity exclusivity, expiring May 13, 2027, for both Mounjaro and Zepbound, although Zepbound was approved in November 2023.

Four years after Mounjaro's approval was May 13, 2026. FDA's list of Paragraph IV certifications records that date as the first submission of such applications for both brands, and counts up to 13 ANDAs for the Mounjaro autoinjector and up to 12 for Zepbound's, depending on strength.

An applicant that makes a Paragraph IV certification must notify the patent holder. Lilly received the notice letters in these cases between July 1 and July 16, 2026. A patent holder that sues within 45 days of receiving notice holds back FDA approval, and Lilly filed all 14 complaints on August 6, inside every one of those windows. Each complaint pleads that submitting the ANDA was itself an act of infringement under 35 U.S.C. 271(e)(2)(A), the provision that lets a patent holder sue before any generic product reaches the market.

Why the stay runs to November 2029

A timely suit ordinarily keeps FDA from making an approval effective for 30 months from the patent holder's receipt of notice. Counted from these notices, that would have ended in January 2029. When the suit comes in the fifth year after a new chemical entity's approval, the statute extends the 30 months until seven and a half years have passed since that approval. Seven and a half years after May 13, 2022 is November 13, 2029, and every one of the 14 dockets records that date as its stay deadline.

The stay ends sooner if the district court decides before then that the patents are invalid or not infringed, in which case approval can take effect from the date of the judgment. The stay governs when an approval can take effect, not whether FDA reviews the applications in the meantime.

The ten patents

All ten are listed in the Orange Book for Mounjaro, Zepbound or both:

The '780 patent is the only one the Orange Book lists as claiming the drug substance, tirzepatide itself. Seven complaints assert it: those against Amneal, Dr. Reddy's, Eugia, Hikma, MSN, Rio and Sandoz. The other seven assert the remaining nine patents and not the '780. The complaints do not say why.

In every case Lilly asks the court to order that any FDA approval of the defendant's ANDAs take effect no earlier than the expiration of the last asserted patent, including any extensions, and to bar the defendant from selling its generic before then. It also asks for damages if a defendant launches before that date, and for attorneys' fees. FDA's Paragraph IV list gives the last qualifying patent expiration as December 30, 2041 for Mounjaro and July 22, 2039 for Zepbound.

The fourteen cases

Unless noted, an application covers the single-dose autoinjector pen in all six of its strengths, and the first ANDA number listed is for Mounjaro and the second for Zepbound. Dates are in 2026, and status is as of November 18.

Where the cases go from here

The cases are at their earliest stage, with the stay running to November 13, 2029 in all 14. What FDA recommends a generic tirzepatide application contain is set out in its product-specific guidances for Mounjaro and Zepbound, both revised in draft on July 28, 2026, the same day FDA withdrew its 2021 guidance on synthetic copies of peptides first approved as recombinant DNA products. Our post on the July guidances covers both actions.

These are cases about ANDAs, the applications that lead to FDA-approved generic copies of Mounjaro and Zepbound. Each complaint is directed at the named applicants and their proposed generic products, and none addresses products sold for research use.

Sources

PeptideScouter indexes vendor prices for research chemicals sold for laboratory use only, not for human consumption. Nothing here is medical, legal, or investment advice. We earn affiliate commissions on some outbound vendor links - see our disclosure.